TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.51, sa.4, ss.1953-1959, 2021 (SCI-Expanded)
Background: The efficacy of mepolizumab has been largely demonstrated in clinical trials in patients with severe eosinophilic asthma (SEA). However, reports on experience with mepolizumab in a real-life cohort are limited. Moreover, data about the effectiveness of mepolizumab on small airways is scarce. Objective: This study evaluated the effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, blood eosinophils, steroid dependence and small airways in a real-life cohort of patients with SEA.